Phase I Study of Bevacizumab, Everolimus, and Panobinostat (LBH-589) in Advanced Solid Tumors

PURPOSE: To define the maximum tolerated dose, clinical toxicities, and pharmacodynamics of bevacizumab, everolimus and panobinostat (LBH-589) when administered in combination in patients with advanced solid tumor malignancies. EXPERIMENT DESIGN: Subjects received 10 mg of panobinostat three times w...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Strickler, John H., Starodub, Alexander N., Jia, Jingquan, Meadows, Kellen L., Nixon, Andrew B., Dellinger, Andrew, Morse, Michael A., Uronis, Hope E., Marcom, P. Kelly, Zafar, S. Yousuf, Haley, Sherri T., Hurwitz, Herbert I.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3793400/
https://ncbi.nlm.nih.gov/pubmed/22744359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1911-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky